MedTrace Logo

Treatment Compliance in Children and Adolescents on ADHD Medication

NCT00540826 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 518

Last updated 2009-08-27

No results posted yet for this study

Summary

The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine clinical setting. Compliance will be assessed using the Pediatric Compliance Self-Rating (PCSR) Instrument. A patient will be considered as compliant at a given visit, if the PCSR score is at least 5, corresponding to taking the medication at least often.

Conditions

  • ADHD

Interventions

DRUG

Atomoxetine

in-label use

DRUG

stimulants (any approved ADHD medication)

in-label use

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-615-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Completion
2009-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00540826 on ClinicalTrials.gov